The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, the APOE*3Leiden...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouwer, Marianne G., Pieterman, Elsbet J., Verschuren, Lars, Caspers, Martien P. M., Kluft, Cornelis, Garcia, Ricardo A., Aman, Jurjan, Jukema, J. Wouter, Princen, Hans M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005845/
https://www.ncbi.nlm.nih.gov/pubmed/29946549
http://dx.doi.org/10.3389/fcvm.2018.00055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005845/
https://www.ncbi.nlm.nih.gov/pubmed/29946549
http://dx.doi.org/10.3389/fcvm.2018.00055

Ejemplares similares